HIVACAR aims to provide a new therapeutic alternative to “cART for life” (combined antiretroviral therapy) and will address the individual and public health limitations associated with this standard of care:
- Cost of the medication.
- Mandatory high adherence to medication for life.
- Side effects.
- Risk of resistances developement.
An innovative strategy based on the patient’s immune system, safe, affordable and scalable to achieve the functional cure of HIV-1 infection will be tested in a Phase I / IIa clinical trial. In addition, the ethical, economic and psychosocial challenges associated with a functional HIV cure will be investigated to provide a complementary alternative to the current treatment standard.
𝘼 𝙘𝙤𝙢𝙢𝙪𝙣𝙞𝙩𝙮-𝙡𝙚𝙙 𝙥𝙨𝙮𝙘𝙝𝙤𝙨𝙤𝙘𝙞𝙖𝙡 𝙨𝙪𝙧𝙫𝙚𝙮 𝙖𝙗𝙤𝙪𝙩 𝙃𝙄𝙑 𝙧𝙚𝙢𝙞𝙨𝙨𝙞𝙤𝙣 𝙖𝙞𝙢𝙨 𝙩𝙤 𝙖𝙨𝙨𝙚𝙨𝙨 𝙩𝙝𝙚 𝙠𝙣𝙤𝙬𝙡𝙚𝙙𝙜𝙚 𝙖𝙣𝙙 𝙚𝙭𝙥𝙚𝙘𝙩𝙖𝙩𝙞𝙤𝙣𝙨 𝙖𝙢𝙤𝙣𝙜 𝙥𝙚𝙤𝙥𝙡𝙚 𝙡𝙞𝙫𝙞𝙣𝙜 𝙬𝙞𝙩𝙝 𝙃𝙄𝙑
Are you a person living with #HIV based in Belgium, Denmark, France or Spain? The European AIDS Treatment Group (EATG), HIV community partner within the #HIVACAR initiative, invites you to fill in 𝙖 𝙨𝙪𝙧𝙫𝙚𝙮 to help better understand 𝙮𝙤𝙪𝙧 𝙠𝙣𝙤𝙬𝙡𝙚𝙙𝙜𝙚 𝙖𝙗𝙤𝙪𝙩 𝙃𝙄𝙑 𝙧𝙚𝙢𝙞𝙨𝙨𝙞𝙤𝙣...
Currently, over 36 million people worldwide are infected with HIV, most of them living in developing countries1. In 2014, 1.2 million people died of AIDS-related illnesses…